Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

This FDA News Month in Review provides a round-up of regulatory decisions from April 2025.


FDA News Recap: April 2025

This FDA News Month in Review provides a round-up of regulatory decisions from March 2025.


FDA News Recap: March 2025

The biosimilars are expected to become available in the US in June 2025. 

FDA Approves Celltrion’s Denosumab Biosimilars for Bone Loss Indications

Recommendations have been largely preserved since 2018 and the USPSTF acknowledged the need for more research and better risk assessment tools.

USPSTF Finalizes 2024 Osteoporosis Screening Recommendations 

CT-P41 had similar rates of bone mineral density increases and adverse events in data presented at the ACR 2024 Convergence. 

Denosumab Biosimilar Demonstrates Equivalent Efficacy, Safety in Phase 3 Trial 

Allegheny Health Network: A Pioneer in the Prevention and Care of Osteoporosis

Fragility fractures occur every minute in France, totaling 500,000 annually. A report calls for expanding fracture liaison services to address the growing osteoporosis burden.

New Report Reveals 1 Fracture Occurs Every Minute in France’s Population

Both treatment arms experienced significant improvements in measured parameters from baseline, although these were not all statistically significant. 

Teriparatide Biosimilar Demonstrates Therapeutic Equivalence in Postmenopausal Women With Osteoporosis 

The mean percentage change from baseline in lumbar spine bone mineral density was comparable between treatment groups at 18 months. 

Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months

Patients with RA had an increased risk of fractures compared with controls, with significant baseline predictors for future fractures identified as higher age, low body mass index, and low bone mineral density. 